Small Cap Polaryx Picks Research Partner, Stock Surges on Phase 2 Trial Plans
I'm PortAI, I can summarize articles.
Polaryx Therapeutics (NASDAQ: PLYX) shares surged 46.06% to $3.52 following the selection of a research organization for its SOTERIA Phase 2 trial. This trial will evaluate the safety and efficacy of PLX-200 for lysosomal storage disorders, with plans to initiate in the first half of 2026. The FDA granted a safe to proceed letter in October 2025, and the trial aims to gather data that could lead to conditional marketing authorization if successful.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: benzinga_article The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments